News

The phase 2 study, dubbed Hermione, evaluated MM-302, an antibody-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer patients who had earlier been treated with trastuzumab (Herceptin), pertuzumab (Perjeta)

Fluor has been providing basic design services since Novo Nordisk announced plans for the new facility in August 2015 and now will be executing the full scope of

Cabotegravir is yet to be approved by regulatory authorities anywhere in the world.  It is the first injectable to be studied for efficacy in pre-exposure prophylaxis. Dubbed HPTN 083, the 4,500-subject

This collaboration will grant Taiho access to X-Chem’s DEX technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of

These products will be packaged and marketed as store brands or retailer 'own label' brands and provide consumers with high-quality, value alternatives to Nicorette White Ice Mint Gum.

The extension is the result of the submission of additional data by Genentech regarding the commercial manufacturing process of OCREVUS, which required additional time for FDA review. The

Under the deal, Bristol-Myers will pay $50m upfront and will be solely responsible for worldwide clinical development and commercialization activities associated to the NG-348 virus. The deal also

The study will investigate the effects of once-daily closed triple combination therapy fluticasone furoate/ umeclidinium/vilanterol compared to therapy with the once-daily dual combination therapy, Relvar/Breo(R) (FF/VI). Comprising three

COMPASS is a randomized, double-blind, placebo-controlled, 26-week Phase 3 study evaluating volanesorsen in 113 patients with severe hypertriglyceridemia. The average incoming triglyceride level of patients in the study